Compliance with guidelines for the perioperative management of vitamin K antagonists  by Steib, Annick et al.
Thrombosis Research 133 (2014) 1056–1060
Contents lists available at ScienceDirect
Thrombosis Research
j ourna l homepage: www.e lsev ie r .com/ locate / th romresRegular ArticleCompliance with guidelines for the perioperative management of
vitamin K antagonists☆,☆☆Annick Steib a,⁎,1, Paul-Michel Mertes a,1, Emmanuel Marret b,1, Pierre Albaladejo c,1, Jacques Fusciardi d,1
a Department of Anaesthesiology, University Hospital (Nouvel Hôpital Civil), Strasbourg, France
b Department of Anaesthesiology, Hôpital Tenon, Paris, France
c Department of Anaesthesiology, University Hospital, Grenoble, France
d Department of Anaesthesiology, University Hospital, tours, FranceAbbreviations: HAS, French National Authority for Hea
LMWH, low molecular weight heparin; INR, international
☆ This work was presented as a communication durin
Meeting in Paris, september 2011.
☆☆ This register was declared to the national commission
⁎ Corresponding author at: Department of Anaesthesiol
Hôpital Civil, 1 place de l’hôpital, 67091 Strasbourg cedex,
fax: +33 3 69 55 18 10.
E-mail address: annick.Steib@chru-strasbourg.fr (A. St
1 French College of Anaesthetists and Intensivists.
http://dx.doi.org/10.1016/j.thromres.2014.03.053
0049-3848/© 2014 The Authors. Published by Elseviea b s t r a c ta r t i c l e i n f oArticle history:
Received 19 October 2013
Received in revised form 12 March 2014
Accepted 31 March 2014
Available online 4 April 2014
Keywords:
Vitamin K Antagonist
Guidelines
Register
Continuing Professional Development
Quality
Evaluation of practice
Introduction: Perioperative vitamin K antagonistmanagement is an issue of concern inmany countries. The avail-
ability of best practice guidelines meets health professionals’ needs, but compliance is uncertain and should be
assessed.
Materials and methods: Our aim was to assess practitioner compliance with the guidelines on perioperative VKA
management issued by the French National Authority for Health through a national register set up in partnership
with the French College of Anaesthetists and Intensivists. Seven sections of data entrywere focused on perioper-
ativemanagement of VKAs for elective or emergency procedures. High-risk patients were identiﬁed. Compliance
with guidelines was calculated per item
Results: 932 charts were completed between October 2009 and December 2010. VKA therapy was interrupted in
74% (622/837) of elective procedures and bridged in 69% cases (428/622) mainly with LMWH. According to
guidelines, bridging was strongly recommended in 39% high-risk patients (175/394) but 13% of these (23/175)
received no bridging. Bridging was overused in 60% of low risk patients (242/406). Other compliance rates
were as follows: (i) administration of therapeutic enoxaparin doses (=200 IU/kg/day): only 18% of high-risk
patients (18/98), (ii) INR measurement on evening prior to the procedure 65% (525/803), (iii) concomitant pro-
thrombin complex concentrate and vitamin K administration in emergency surgery 24% (21/87), (iv) postoper-
ative therapeutic enoxaparin doses: only 20% despitewidespread prescription. The incidence rate of bleeding and
thrombotic events was 7.1% and 0.96% respectively.
Conclusions: These poor compliance rateswith guidelines suggest that the knowledge-to-action transfer planwas
inadequate and that further interventions are required.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Vitamin K antagonist (VKA) management is an issue of concern. The
risks of poor VKA management are well known. Perioperatively, it is
necessary to achieve a balance between thromboembolic risk, which
on VKA interruption is greatest in high-risk patients, and bleeding risk
on VKA maintenance or overdosage.lth; VKA, vitamin K antagonist;
normalised ratio.
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ogy, University Hospital, Nouvel
France. Tel.:+33 3 69 55 10 91;
eib).
r Ltd. This is an open access article uIn 2008, the French Authority for Health published national guide-
lines aiming to reduce serious adverse events (thromboembolism or
bleeding) when patients on VKAs underwent elective or emergency
interventions [1]. Key recommendations were deﬁned as follows.
Patients were stratiﬁed into two risk categories for thromboembolism.
The high-risk category comprised patients with (i) a MHV, (ii) atrial
ﬁbrillation with a history of transient ischemic attacks, stroke, systemic
embolic event, (iii) recent (b3 months) or recurrent VTE (deep vein
thrombosis or pulmonary embolism). All other patients were stratiﬁed
as low risk. In an elective setting, bridging anticoagulation is recom-
mended during interruption of VKA therapy (low molecular weight
LMWH or unfractioned heparin UFH) in high risk patients whereas low
risk patients do not require preoperative bridging. In an emergency set-
ting, prothombin complexe concentrates (PCCs) and vitaminK should be
administered simultaneously to correct the international normalised
ratio (INR) before the procedure. Postoperatively, VKA treatment shouldnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Types of procedures.
Table 1
Demographic data of the 932 entries.
Age (years) 74 [95% CI: 73.6 – 75]
Sex ratio M/F 553/379
ASA Status (%)
I 2 (1%)
II 214 (23%)
III 684 (73%)
IV 32 (3%)
VKA treatment n (%)
Acenocoumarol 86 (9%)
Coumadine 61 (7%)
Fluindione 785 (84%)
Indications n (%)
MHV 87 (9%)
AF 591 (64%)
VTE 191 (20%)
Others 63 (7%)
Mmale, F female, ASA: American Society of Anesthesiologists, MHV:mechanical
heart valve, AF: chronic atrial ﬁbrillation, VTE: venous thromboembolism.
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risks. Therapeutic doses of heparin should be introduced at least 48 h
following the procedure in high thrombotic risk patients until obtaining
the target INR [1].
The effectiveness and implementation of guidelines needs to be
evaluated. Methods including continuing medical education meetings,
workshops, audit and feedback, printed educational materials have
shown objective limitations on their effects on professional practice
and patient outcome [2–4]. A fairly recent method of assessing compli-
ance with good practice guidelines is the setting up of a register based
on criteria drawn from standardised protocols allowing therefore the
analysis of the degree of compliance with recommendations.
The aim of the present study was to assess practitioner compliance
with the published guidelines through a national register set up by
The French College of Anaesthetists and Intensivists, in partnership
with the French National Authority for Health (HAS).
Materials and Methods
The French College of Anaesthetists and Intensivists has the
agreement to validate continuing professional development (CPD) by
different quality tools previously certiﬁed by the French National
Authority for Health (HAS). By completing a minimum of 10 charts of
the register during one year of practice, and comparing their own re-
sults with guidelines, voluntary members of the College could therefore
validate their own professional practice evaluation.
The items of the register were set up by members of the working
group who were involved in the guidelines development [1]. The
register was available on line (Clin-Info SA Lyon France) on the website
of the French College (www.cfar.org). It was declared to the national
commission CNIL (Nb 1397646) which is responsible for ensuring that
information technology remains at the service of citizens, and does
not jeopardize human identity or breach human rights, privacy or indi-
vidual or public liberties.
Practitioners had to complete 7 sections on data entry giving the
following informations: demographic data, type of procedure (surgery
or invasive procedure, scheduled or emergency (b12 h) procedure),
indications for VKAs therapy [mechanical heart valve (MHV), chronic
atrial ﬁbrillation (AF), venous thromboembolism (VTE) or other], type
of anticoagulant (ﬂuindione, acenocoumarol, coumadin) and duration
of VKA therapy, patient history, preoperative management for an elec-
tive procedure (last known INR, preoperative VKA interruption and
bridging, INR measurement on the eve prior to the procedure and
management if INR N1.5), preoperative management in an emergency
setting (INRmeasurement, administration of prothrombin complex con-
centrates (PCCs), vitamin K, fresh frozen plasma or other antidotes),
postoperative management (postoperative bridging, VKA therapy re-
sumption), and in-hospital complications (bleeding, thromboembolism,
or other).
Compliance with guidelines was assessed on the following criteria:
(i) preoperatively in an elective setting: justiﬁcation for VKA interrup-
tion, justiﬁcation for a bridging approach, administration of therapeutic
twice doses per day in patients with MHVs or atrial ﬁbrillation when
heparin bridging was required, INR measurement on the evening prior
to the procedure. administration of 5mg vitamin K if INR N1.5, and pro-
cedure scheduled in the morning; (ii) preoperatively in an emergency
setting: INR measurement, concomitant injection of PCCs and 10 mg
vitamin K; (iii) postoperatively: date of VKA resumption, postoperative
administration of therapeutic heparin doses within 48 h, and two INR
measurements separated by 24 h within the therapeutic range before
stopping heparin. All these criteria fulﬁlled the published recommenda-
tions [1].
R language was used for descriptive statistical analysis. Results were
expressed as means [95% CI] or median [range]. Percentage compliance
with guidelines was calculated for the key recommendations as deﬁned
above. The expected target was 85% +/− 5%.Results
Demographics
A total of 79 centres entered patients into the register between
October 2009 and December 2010. Overall, 976 entries were recorded
(Fig. 1) and 932were suitable for analysis. Fourty four charts comprised
no preoperative informations. The indications for VKA therapy and
demographic data are reported on Table 1.Preoperative Management in the Elective Setting
VKA therapy was not interrupted preoperatively in 26% (215/837)
elective procedures. The most common elective surgical and elective
invasive procedures without VKA interruption were, respectively, eye
surgery (157/184, 85%) and digestive endoscopy (18/31, 58%).
VKA therapy was interrupted preoperatively in 74% (622/837)
patients. The interval between VKA interruption and the procedure
was 6 days (21%), 5 days (59%), 4 days (12%) or 3 days (6%).
One third of them (194/622) received no heparin bridging whereas
69% (428/622) received bridging mainly with low molecular weight
heparin (enoxaparin). 394 patients treated for mechanical heart valve
failure (58), chronic atrial ﬁbrillation (243) or venous thromboembo-
lism (93) were concerned. According to guideline recommendations,
bridging was initiated in 152/175 patients who were classiﬁed at
high-risk. However, 23 high risk patient (13%) did not receive heparin
bridging (2/60 MHVs, 8/50 AF and 13/65 VTE) after VKA interruption.
Table 2
Bridging strategy in an elective setting according to the thromboembolic risk [1].
High risk patient
N (%)
Low risk patient
N (%)
Mechanical heart valve 60
Bridging 58 (97%) /
No bridging 2
Atrial ﬁbrillation 50 345
Bridging 42 (84%) 201(58%)
No bridging 8 144
Venous thromboembolism 65 61
Bridging 52 (80%) 41 (67%)
No bridging 13 20
Bridging in high risk patients: 152/175 (87%).
Bridging in low risk patients: 242/406 (60%).
1058 A. Steib et al. / Thrombosis Research 133 (2014) 1056–1060One the other hand, bridging was overused in 60% of low risk patients
(242/406) with AF and VTE [Table 2].
Low molecular weight heparin (LMWH), subcutaneous (SC)
unfractionated heparin (UFH) and intravenous (IV) UFH were used for
bridging in 83%, 11% and 1% respectively. Fondaparinux (not recom-
mended) was prescribed to 23 patients (5%). Non-therapeutic doses of
enoxaparin (b200 IU/kg/day) were used in 87% of all patients and in
82% of high-risk patients (80/98) receiving bridging. Enoxaparin was
injected twice daily in 74% of patients.
INR was measured on the evening prior to the procedure in 65%
of patients. Mean INR was 1.35 [95% CI: 1.32-1.38] in patients with
preoperative VKA interruption and 2.59 [95%CI: 2.35-2.82] in patients
without interruption.
The procedure was scheduled between 7 a.m. and 1 p.m. in 72% of
documented cases.
Compliance with key recommendations for preoperative VKA
management is summarised in Table 3.
Preoperative Management in the Emergency Setting
Among the 95 emergency procedures, 87 were surgical procedures
(47 orthopaedics, 16 neurosurgery including 14 subdural or intracranial
haematomas, 14 gastrointestinal, and 10 other).
The INRwas known at the time of surgery in 92% of patients (80/87).
Mean INR values are given in Table 4. Only 21/87 patients (24%)
received PCCs concomitantly with vitamin K as recommended. All 16
neurosurgical cases received PCCs but 4/16 did not receive concomitant
vitamin K. Only 4 of the 47 orthopaedics cases received PCCs but 33/47
received vitamin K alone. Practice varied evenmorewidely for digestive
surgery cases.
Only 6 of the 29patients administered PCCs received a dose adjusted
to bodyweight (1 ml/kg) as recommended.Median vitamin K dosewas
10 mg (range 2–20). Vitamin K was administered IV in 34/59 patients
(57%).
Postoperative Management
A total of 582 entries documented postoperative management after
VKA interruption. They related to 28% at high risk of thromboembolismTable 3
Identiﬁcation of malpractice and compliance rate with guidelines in the preope
Malpractice according to guidelines
No bridging despite risk factors
Bridging in low-risk patients
Administration of non-therapeutic enoxaparin doses *
Not twice daily injections in MHV and AF patients
INR not measured on evening before procedure
Surgery not scheduled in the morning
VKA vitamin K antagonist; MHV, mechanical heart valve; AF, atrial ﬁbrillation;and 72% at low risk. Postoperative heparin was administered to 447
patients (77%). Among the 135 patients receiving no postoperative
heparin, 104 (77%) had received no preoperative bridging even though
17 were in the high-risk category. VKA was resumed in 70% during the
postoperative observation period, in most cases within 0 to 4 days.
Postoperative heparin was administered as from Day 0 in 96% high
risk patients and 64% low risk patients. Enoxaparin was widely pre-
scribed but the doses were therapeutic in 20% of cases only (Fig. 2).
Half the patients given SC UFH did not receive therapeutic doses.
Postoperative heparinwas not administered to 27% emergency cases.
A therapeutic dose of LMWH was given to 7/67 emergency cases only.
Postoperative Complications
Among the 636 elective surgical procedures, 193 (30%)were consid-
ered at high risk for bleeding [5].
In-hospital complications were 9/932 thromboembolic events
(0.96%), 67/932 bleeding events (7.1%), and 44/932 cardiovascular,
pulmonary and/or septic complications (5%).
Bleeding complications occurred in 10 emergency situations and 57
elective settings. Eighteen patients required reoperation and 31 de-
crease in haemoglobin level N 2 g/dl were observed. VKAswere stopped
in 25 patients and heparin was stopped in 24 patients. A total of 28 red
blood cell packs were transfused to 36 patients. Most bleeding events
were observed on the two ﬁrst postoperative days.
Thrombotic and bleeding events were mainly reported in respec-
tively 7 and 43 patients with AF. Among these, 33/43 bleeding events
occurred in low thrombotic risk patients; 70% of them (23/33) received
preoperative bridging whereas more than 50% of them had a high
bleeding risk procedure.
Discussion
VKA management is an issue of concern. Standardized protocols for
VKAmanagement have been developed in other countries with similar
recommendation of management relied to the risk category of the
patients [5].
According to the above results, at least 30% of patients treated with
VKAswere not receiving the care recommended by the French Authority
for Health during the perioperative period. This was despite widespread
promotion of the guidelines after their publication (presentations at
national and regional meetings, articles in scientiﬁc journals, posting on
the HAS website). Our result is in line with reports on other guidelines
evaluation indicating that 20 to 40% of patients do not receive recom-
mended care [6,7].
The most blatant deviations related to preoperative bridging.
Surprisingly, 56% of low-risk patients received heparin bridging. Perrin
et al. [8] found also an overuse of bridging anticoagulation in a 62
patients at low risk for thromboembolism scheduled for rhythm device
surgery. They observed 3 pocket hematomas and one episode of signif-
icant bleeding reporting therefore an incidence rate of 8 % bleeding
events contrasting with none thromboembolic complications. In our
study, as many as 23 out of 33 atrial ﬁbrillation patients with early
postoperative bleeding were at low thrombotic risk and neverthelessrative setting for elective procedures.
N (%) Compliance rate
with guidelines (%)
23/175 (13%) 87
242/406 (60%) 40
232/265 (87%) 23
49/187 (26%) 74
278/803 (35%) 65
221/789 (28%) 72
INR, International Normalised Ratio. * b 200 UI/kg/day.
Table 4
VKA management in emergency surgery setting.
Orthopaedics
n = 47
Neurosurgery
n = 16
Gastrointestinal
n = 14
Mean INR [95% CI] 1.78 [1.57-1.98] 2.97 [2.35-3.60] 2.08 [1.65-2.46]
PCCs + Vit K (n) 3 12 4
Vit K alone (n) 33 0 3
PCCs alone (n) 1 4 3
Nothing (n) 8 0 3
Delay INR-Surgery (h) 13 3.6 6.5
INR, International Normalised Ratio; PCCs, prothrombin complex concentrates; Vit K,
vitamin K;
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risk for most of them. Whether no-bridging would have spared these
patients is impossible to assess but is a question worth asking.
Widespread preoperative bridging in low-risk patients may be due to
misunderstanding of the guidelines on the part of the practitioners or
unjustiﬁed overcautiousness. The rationale for bridgingwas not explored
as the primary objective of the register was to assess compliance to
guidelines without inﬂuencing spontaneous practice.
Another issue of concern is that the perioperative heparin doses
used in our study were not therapeutic in around 80% of the patients.
This was also described in a prospective observational study including
492 patients receiving periprocedural bridging anticoagulation in 9 US
hospitals. Seven centers used therapeutic doses in an average of 22%
of cases as observed in our register whereas only two centers treated
more than 80% of their patients with full dose heparin started a median
of 1 day postoperatively [9]. Aggressive anticoagulationwas signiﬁcantly
associatedwith bleeding complications. The authors reported a bleeding
rate of 6.2% and thromboembolic events in 0.8% of cases. Although
reduced initial doses might have been related to some considerations
regarding a possible immediate postoperative increased risk of bleeding
according to the attending team, this is not likely to be the case since the
doses were stable over time and were not increased 48 hours postoper-
atively as recommended for resuming therapeutic doses according to the
HAS guidelines. In our study, the overuse of bridging (even with non-
therapeutic doses) associated with a high bleeding risk procedure
might have contributed to early postoperative bleeding complications
as observed above [8,9].
As the risks of poor VKA management are well known, we thus
expected better compliance with our guidelines. Reasons that have
been put forward for non-compliance are lack of practitioner awareness
owing to information overload, guidelines considered inapplicable
in clinical practice, lack of visibility on expected outcomes, lack of
appropriation or motivation, and resistance of patients, their family or
environment [10–13]. In addition, the supporting evidence is often
subject to considerable bias and consequently suspicion, and guideline
implementation is seldom assessed [14,15]. Awareness that researchFig. 2. Compliance (% of patients) with postoperative administration of therapeutic
enoxaparin doses (D0-D3: Day 0 to Day 3; M: Morning; E: Evening).ﬁndings are not making their way into practice in a timely fashion is
growing, and ways to minimize the so-called knowledge-to-action gap
are needed although little is yet known on how to improve care in
many settings [16]. In the Deming cycle, monitoring knowledge use –
in our case instrumental use - is a key step in improving quality of
care. Good compliance would depend on sustained monitoring after
identiﬁcation of a precise target, and it may thus be wishful thinking
to expect an 85% compliance rate with our multiple targets. However,
in a three-hospital healthcare system in the US, a strategy focused on
improving anticoagulant safety across the continuum of care resulted
in a signiﬁcant reduction in adverse events [17]. Boosting implementa-
tion by passive information dissemination is generally thought to be
ineffective in changing practices, whereas combining several types of
intervention, aswe did, is better [18]. However, promotion of our guide-
lines by HAS and the French College of Anaesthetists and Intensivists
among potential users seems to have been inadequate. Further inter-
ventions are doubtless needed. For instance, computerized reminders
may prove useful in a setting as complex as perioperative VKAmanage-
ment [15]. Othermeans have been recently proposed by the French Col-
lege of Anaesthetists and Intensivists to improve compliance including
on line prescription tools and clinical cases with MCQs referring to
guidelines, organization of interactive topics during national meetings.
Some limitations might be highlighted. Guidelines related to
perioperative VKA management are based in large part on “expert”
opinion because the lack of high level evidence in both French and US
recommendations especially for bridging anticoagulation (grade 2C in
[5]). One can therefore query their relevance to the practitioner. This
limitation was discussed in a recent editorial published by Hessel and
Levy [19]. They pointed the need for more high level evidence studies
allowingmore enthusiastically endorsement by clinicians. Other limita-
tions of our resultsmay be related to the nature of this declarative study.
The objectiveswere not to enroll consecutively all thepatientswith VKA
treatment during one year period but to incitate voluntary members of
the French College of Anaesthetists and Intensivists to assess their own
practice through a fairly recent method of evaluation which could lead
them to validate a process of professional practice evaluation. The valid-
ity of the results may be questionable as consecutive patients were not
included and no speciﬁc monitoring provided. However as for all sur-
veys of spontaneous declaration, the exact incidence of any incident
cannot be accurately determined but effective signals of risk, in this
case, poor practicemanagement can be efﬁciently identiﬁed. Moreover,
our results probably overestimate the compliance with guidelines as
they were provided by practitioners interested by the challenge of
perioperative VKA management. Thus general malpractice in our
country might be even worse than that reported by the responders to
our register which highlighted speciﬁc points of putative progress.
The development of new oral anticoagulants, with an allegedly
reduced incidence of adverse events in large clinical trials, may prompt
new guidelines, but should not put off implementation of measures to
improve compliance with the recommendations on existing VKAs
which continue to be administered to large numbers of patients
especially for MHV [20,21]. These new oral anticoagulants still have to
undergo strict post-marketing surveillance to avoid patients being at
risk of premature complications. Setting up a new register might be a
fair method of evaluation of practice which could be extended to
other countries.
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